Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4064912 in Healthy Participants and Participants With Overweight or Obesity
NCT07152002Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Countries
- 2
01
Overview
Phase 1, randomised trial of LY4064912 in obesity and Overweight (7 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at 27 weeks. Started Aug 2025; status: terminated.
02
Drugs
LY4064912
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07152002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152002.